Fulcrum Therapeutics Inc Dossier - Source-backed chat

Fulcrum Therapeutics Inc

FULCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.05

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.68Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $280.8M

Enterprise Value $238.2M

Shares Outstanding 77.1M diluted

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Fulcrum Therapeutics has transitioned into a cash shell following consecutive clinical failures. In September 2024, the company suspended its Phase 3 FSHD program for losmapimod. On June 1, 2026, Fulcrum announced the discontinuation of its remaining clinical asset, pociredir, for sickle cell disease due to FDA concerns regarding malignancy risks associated with PRC2 inhibitors. Consequently, the board approved an 85% workforce reduction, leaving only 9 full-time employees, and initiated a strategic review to explore mergers, acquisitions, or asset sales. The investment thesis is now entirely centered on capital preservation and the potential to unlock value from its $333.3 million cash balance (as of March 31, 2026) through a strategic transaction.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$5.83

High · most bullish analyst$18.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The strategic review process is prolonged, leading to excessive cash burn on executive retention and administrative overhead, or the company is liquidated at a steep discount to its current cash balance due to unforeseen liabilities.

Base CaseCentral scenario

The company successfully preserves the majority of its cash balance (approximately $333.3 million as of Q1 2026, minus restructuring costs of $4.2 million and minimal wind-down burn) and executes a reverse merger or sale that values the company close to its net cash value.

Bull CaseUpside scenario

The bull case for Fulcrum Therapeutics centers on its transition into a cash-rich shell or M&A target, leveraging its substantial cash balance of approximately $333.3 million (as of early 2026) to execute a strategic transaction, merger, or acquisition that can unlock shareholder value following the discontinuation of its lead clinical program pociredir.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong cash position of $333.3 million as of March 31, 2026, providing a substantial valuation floor relative to its depressed market capitalization.
Rapid implementation of cost-saving measures, including an 85% workforce reduction to preserve capital during the strategic review.
Engagement of Leerink Partners to actively explore strategic alternatives to maximize shareholder value.

Key Investment Risks

Complete lack of active clinical-stage pipeline assets following the discontinuation of both losmapimod and pociredir.
Potential for cash dissipation through restructuring charges ($4.2 million estimated in Q2 2026), executive retention payments, and ongoing administrative overhead.
Risk that the strategic review fails to identify a value-enhancing transaction, leading to liquidation at a discount.

Thesis Invalidation Triggers

Failure to announce a strategic transaction within the next 6-12 months.
Significant unexpected cash burn or legal liabilities arising from the discontinued clinical programs.
Departure of the remaining core management team before a transaction is finalized.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.